According to MarketsandMarkets, the Transfection Technologies Market is expected to grow from USD 1.2 billion in 2023 to USD 1.8 billion by 2028, achieving a CAGR of 9.4%. This growth is fueled by the increased need for advanced therapies due to chronic disease prevalence and higher R&D spending. However, the market is restrained by factors such as limited efficiency and stringent regulatory standards.
The kits & reagents segment accounted for the largest share by product type in the transfection technologies market in 2022.
By product type, the transfection technologies market has been further categorized kits & reagents and equipment. Kits & reagents accounted for the largest share of the transfection technologies market in 2022. The large share of this segment can be attributed to the increasing demand for high-quality reagents to transfect nucleic acids into cells. Additionally, the growing R&D activities in the biopharmaceutical industry and the increased initiatives by governments in various countries to strengthen their healthcare capabilities are supporting the growth of this market.
The viral vector-based transfection segment is expected to grow at a higher rate during the forecast period.
Based on the method, the transfection technologies market has been segmented into physical transfection, biochemical based transfection, and viral vector-based transfection. In 2022, the physical transfection segment accounted for the largest share of the transfection technologies market. However, the viral vector-based transfection segment is expected to grow at a higher growth rate during the forecast period of 2023-2028. This can be attributed to the increasing demand for advanced therapies and growing research activities in the field of life sciences and cell biology.
The therapeutic delivery segment accounted for the largest share of the application segment in the transfection technologies market in 2022.
Based on application, the transfection technologies market has been segmented into therapeutic delivery, biomedical research, protein production, and cell-based microarray. In 2022, the therapeutic delivery segment accounted for the largest share of the transfection technologies market. One of the major factors driving the growth of this segment is rising incidences of chronic and rare diseases. Additionally, the rising investments in discovering new ways to develop innovative cell-based products are driving the segment growth.
The pharmaceutical and biotechnology companies segment accounted for the largest share of the end user segment in the transfection technologies market in 2022.
Based on the end user, the transfection technologies market has been segmented into pharmaceutical and biotechnology companies, CROs and CDMOs, academic & research institutes and other end users. In 2022, pharmaceutical and biotechnology companies accounted for the largest share. This can be attributed to the increasing advancements in biopharmaceutical industries. Cell and tissue-based technologies are commonly associated with transfection technologies for cell transfection. Therefore, increasing demand for cell and gene therapy is one of the major factors driving the growth of this segment.
The North America region catered for the largest share of the transfection technologies market in 2022.
The transfection technologies market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). The North America region is witnessing increasing investments and research activities in the field of drug discovery and development. The need for advanced therapies due to rising incidence of cancer has contributed to the demand for transfection technologies.
Key players in the transfection technologies market include Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), Merck KGaA (Germany), Sartorius AG (Polyplus) (Germany), Lonza (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), MaxCyte (US), Revvity (US), Takara Bio Inc. (Japan), Promega Corporation (US), Danaher Corporation (US), BOC Sciences (US), RJH BIOSCIENCES (Canada), Synvolux (Netherlands), Altogen Biosciences (US), BioIVT (US), Incella GmbH (Germany), InvivoGen (France), Phoreus Biotech (US), STEMCELL Technologies (Canada), EZ Biosystems (US), OZ Biosciences (France), chemicell GmbH (Germany).
Study Coverage:
This research report categorizes the transfection technologies market by product type (kits & reagents and equipment), method (physical transfection, biochemical transfection, viral vector transfection), application (biomedical research, therapeutic delivery, protein production, and cell based microarray), end user (pharmaceutical and biotechnology companies, CRO and CDMO, academic and research institutes, and others), and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and trends influencing the growth of the transfection technologies market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product/service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, mergers and acquisitions, and recent developments associated with the transfection technologies market. Competitive analysis of top players and upcoming startups in the transfection technologies market ecosystem is covered in this report.
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
